Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Applied Biosystems v. Micromass

This article was originally published in The Gray Sheet

Executive Summary

Wilmington, Delaware federal court denies motion by Waters Corp. subsidiaries Micromass UK and Micromass to set aside a $47.5 mil. jury award, reached March 15, related to quadrupole mass spectrometer technology patent infringement (1"The Gray Sheet" April 8, 2002, p. 16). Total awarded damages of $52.6 mil. includes $5.1 mil. in pre-judgement interest...

You may also be interested in...



Waters Looking To Douse $48 Mil. Jury Award; Index Composite Flat In Q1

Waters Corp. has asked the presiding judge in a federal patent infringement trial to review a $47.5 mil. jury award against the firm. A decision is expected by the end of May

QUOTED. 30 November 2020. David Hoffmeister.

A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.

Aker BioMarine Plans US NDI Notification For EPA/DHA Formulated To Pass Blood-Brain Barrier

Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel